Topical Infliximab in Autoimmune Eyes With Keratoprosthesis

• Status: Withdrawn
• Trial end date: 2017-04-03
• Target enrollment: 0
• Participant gender: All

Summary

The Boston Keratoprosthesis type I (KPro) is a prosthetic cornea used to treat several causes of corneal blindness. Some categories of patients, including those with auto-immune diseases such as Stevens-Johnson syndrome, toxic epidermal necrolysis syndrome and mucous membrane pemphigoid, have a higher risk of failure for the KPro. Because of chronic inflammation, the cornea supporting the KPro may melt, leading to a higher risk of infection, loss of the KPro and loss of the eye.

Infliximab is an antibody against tumor necrosis factor alpha and is used intravenously to control inflammation in several diseases. It has been used in some cases of corneal melting with significant success.

This study's hypothesis is that infliximab can be successfully used as an eye drop (instead of the usual administration through veins) and that its regular use may prevent melt in eyes with a Boston Keratoprosthesis type I and underlying auto-immune disease.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: James Chodosh, MD, MPH; Massachusetts Eye and Ear Infirmary
• Collaborators: Fonds de recherche en ophtalmologie de l'Université de Montréal; Massachusetts Eye and Ear Infirmary
• Treatments: Infliximab

Criteria

Inclusion Criteria:

• Age between 18 and 80 years

• Able to provide informed consent

• Underlying diagnosis of SJS, TENS, or MMP

• Implantation of a Boston KPro type I

• Able to administer eye medications or have a care giver able and willing to do same

• Negative tuberculosis screening

Exclusion Criteria:

• Active or recurrent ocular or systemic infection

• Chest radiography, QuantiFERON-TB Gold or purified protein derivative (PPD) evidence of active or latent tuberculosis infection

• Indeterminate initial and repeat QuantiFERON-TB Gold results

• History of Bacille Calmette-Guerin (BCG) vaccination within twelve months of screening

• History of latent or active granulomatous infection, including histoplasmosis or coccidioidomycosis, prior to screening

• Chest radiograph within three months prior to the first administration of the study drug that shows an abnormality suggestive of a malignancy or current active infection, including tuberculosis.

• History of a nontuberculous mycobacterial infection or opportunistic infection (e.g. cytomegalovirus, pneumocystosis, aspergillosis) within six months prior to screening

• history of hepatitis B virus

• Methicillin resistant Staphylococcus aureus (MRSA) or vancomycin resistant enterococcus (VRE) infection

• Malignancy diagnosed in the last five years

• Demyelinating disease

• History or current diagnosis of diabetes mellitus (controlled and uncontrolled)

• Heart failure (New York Heart Association class III or IV)

• Pregnancy or breast-feeding

• Scheduled to receive a live vaccine at any time point during study participation

• Allergy to infliximab or any of the compounds in its topical formulation or any chemically-related medication

• Prior or current use of systemic anti-tumor necrosis alpha-α medications or currently receiving treatments of Kineret (Anakinra)

• KPro designs with less than 16 holes in the back plate (to avoid the confounder of corneal nutrition)

• Inability to comply with the instillation of additional drops

• Unable to attend postoperative visits or administer medications, or no care giver available and willing to assist with same